HIGHLY ACTIVE ANTIRETROVIRAL THERAPY-ASSOCIATED REGRESSION OF CYTOMEGALOVIRUS RETINITIS
Authors:
- J. Brian ReedJRJ. Brian Reed
- Jonathan W. BriggsJBJonathan W. Briggs
- J. CHRISTOPHER McDONALDJMJ. CHRISTOPHER McDONALD
- William R. FreemanWFWilliam R. Freeman
- Lawrence S. MorseLMLawrence S. Morse
- 1 August 2001
- journal article
- Published by Wolters Kluwer Health in Retina
- Vol. 21 (4) , 339-343
Abstract
To report the stability of acquired immunodeficiency syndrome (AIDS)-associated cytomegalovirus (CMV) retinitis lesions that have undergone regression in the absence of specific anti-CMV medications owing to highly active antiretroviral therapy (HAART)-generated immune recovery. The initial examination revealed HAART-associated regression of CMV retinitis lesions in eight subjects at two institutions. Patients were monitored for recurrences of CMV activity. CD4+ T-lymphocyte counts and human immunodeficiency virus (HIV) loads were measured. All patients had positive initial responses to HAART with an average HIV load decrease of 2.26 log units (range 0.3-5.57). Mean CD4+ T-lymphocyte count at baseline was 45.6 (range 4-107) and increased by an average of 132.5 (range 7-266) within the first 2 to 4 months of HAART. Patients were observed for an average of 15.5 months (range 11-20 months). Six subjects had a vigorous and sustained response to therapy, achieving an average HIV load of 9,400 copies/mL (3.32 log10 decrease) and CD4+ T-lymphocyte count of 158.2 cells/microL. These patients had no CMV retinitis progression. By contrast, two others who attained an average log10 decrease of only 0.48 had modest and short-lived increases in the CD4+ T-lymphocyte count. These patients experienced reactivation of CMV retinitis after 5 and 7 months, respectively. Regressed CMV retinitis may remain healed for long periods. However, failure of HAART to induce substantial decreases in HIV load may predict poor or unsustainable rises in the CD4+ T-lymphocyte count and presage recurrence of CMV retinitis. Vigilance in ophthalmic examinations is especially mandatory in these subjects.Keywords
This publication has 34 references indexed in Scilit:
- Cytomegalovirus retinitis after the initiation of highly active antiretroviral therapy: a 2 year prospective studyBritish Journal of Ophthalmology, 1999
- Improved Outcome of Cytomegalovirus Retinitis in AIDS Patients After Introduction of Protease InhibitorsJAIDS Journal of Acquired Immune Deficiency Syndromes, 1998
- AIDS and Ophthalmology: A Period of TransitionAmerican Journal of Ophthalmology, 1997
- Regression of Cytomegalovirus Retinitis Associated With Protease-inhibitor Treatment in Patients With AIDSAmerican Journal of Ophthalmology, 1997
- Changing the natural history of HIV diseaseThe Lancet, 1996
- Treatment of Human Immunodeficiency Virus Infection with Saquinavir, Zidovudine, and ZalcitabineNew England Journal of Medicine, 1996
- Alterations in the Immune Response of Human Immunodeficiency Virus (HIV)-Infected Subjects Treated with an HIV-Specific Protease Inhibitor, RitonavirThe Journal of Infectious Diseases, 1996
- A Preliminary Study of Ritonavir, an Inhibitor of HIV-1 Protease, to Treat HIV-1 InfectionNew England Journal of Medicine, 1995
- A Short-Term Study of the Safety, Pharmacokinetics, and Efficacy of Ritonavir, an Inhibitor of HIV-1 ProteaseNew England Journal of Medicine, 1995
- A Prospective Study of the Ophthalmologic Findings in the Acquired Immune Deficiency SyndromeAmerican Journal of Ophthalmology, 1984